Go Pro
NYSEAMERICAN:BPMX

Biopharmx (BPMX) Stock Price, News & Analysis

Biopharmx logo

About Biopharmx Stock (NYSEAMERICAN:BPMX)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
336,508 shs
Average Volume
2.15 million shs
Market Capitalization
$111.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BiopharmX Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative topical and transmucosal therapies for dermatological and oral mucosal conditions. Headquartered in Princeton, New Jersey, the company applies proprietary formulations to address unmet needs in areas such as cutaneous warts, oral mucositis, herpes labialis and psoriasis. In addition to its prescription pipeline, BiopharmX markets OTC skincare products that include moisturizing creams, acne treatments and sun care formulations.

The company’s lead product candidates include BPX-01, a mucoadhesive topical treatment for the prevention of oral mucositis in cancer patients; BPX-04, a topical gel for the treatment of cold sores (herpes labialis); BPX-07, a user-applied therapy for cutaneous warts; and BPX-02, a topical foam for mild-to-moderate plaque psoriasis. Several of these assets have completed Phase 2 clinical studies, and the company is pursuing regulatory interactions aimed at advancing pivotal trials and potential commercialization partnerships.

BiopharmX’s research and development efforts leverage in-house formulation expertise alongside third-party manufacturing and clinical trial networks in the United States. Management has positioned the company to enter strategic alliances for broader geographic rollout upon regulatory approval, with a focus on markets that demonstrate high unmet need for non-systemic dermatological therapies. By combining a diversified product portfolio with a streamlined development model, BiopharmX aims to deliver differentiated treatments to patients and long-term value to shareholders.

AI Generated. May Contain Errors.

Receive BPMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biopharmx and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BPMX Stock News Headlines

TMBRQ Trex Wind-down, Inc.
Trex Wind Down Inc (TMBRQ)
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Form 424B5 Timber Pharmaceuticals, - StreetInsider.com
See More Headlines

BPMX Stock Analysis - Frequently Asked Questions

Biopharmx Corp (NYSEAMERICAN:BPMX) announced its quarterly earnings results on Tuesday, December, 10th. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.64) by $0.96.

Biopharmx shares reverse split on Tuesday, May 19th 2020.The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Shares of BPMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Hawkins (HWKN), Novavax (NVAX) and Protalix BioTherapeutics (PLX).

Company Calendar

Last Earnings
12/10/2019
Today
8/24/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NYSEAMERICAN:BPMX
Previous Symbol
NYSE:BPMX
CIK
N/A
Fax
N/A
Employees
17
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
18,278,000
Free Float
N/A
Market Cap
$111.86 million
Optionable
Not Optionable
Beta
N/A
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NYSEAMERICAN:BPMX) was last updated on 8/25/2026 by MarketBeat.com Staff.
From Our Partners